<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48586">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903928</url>
  </required_header>
  <id_info>
    <org_study_id>0113-CL-1003</org_study_id>
    <nct_id>NCT01903928</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant</brief_title>
  <official_title>An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in
      subjects undergoing allogeneic HCT.  The occurrence of CMV viremia and immunogenicity are
      also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, physical exam and labo-tests</measure>
    <time_frame>for 365 days after HCT</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local reactogenicity</measure>
    <time_frame>for 14 days following each injection</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>protocol-specified reactogenicity scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CMV viremia</measure>
    <time_frame>for 365 days after HCT</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV plasma viral load ≥ 1000 copies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV-specified antiviral therapy</measure>
    <time_frame>for 365 days after HCT</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV-specific AVT(Anti-virus therapy)  initiated for a CMV plasma viral load ≥ 1000 copies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytomegalovirus end-organ disease (CMV EOD)</measure>
    <time_frame>for 365 days after HCT</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV pneumonia, CMV gastroenteritis, CMV hepatitis, et al</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum grade of Graft Versus Host Disease (GVHD)</measure>
    <time_frame>for 365 days after HCT</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Allogeneic Hematopoietic Cell Transplant</condition>
  <arm_group>
    <arm_group_label>ASP0113 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP0113</intervention_name>
    <description>injection</description>
    <arm_group_label>ASP0113 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is planned to undergo either of the following:

               -  Sibling Donor Transplant - 7/8 Human Leukocyte Antigen (HLA)-A, -B, -C, -DRß1
                  match utilizing high resolution typing or 8/8 (HLA)-A, -B, -C, -DRß1 match
                  utilizing low or high resolution typing.

               -  Unrelated Donor Transplant - 7/8 or 8/8 HLA-A, -B, -C, -DRß1 match utilizing
                  high resolution typing.

          -  Subject has one of the following underlying diseases: Acute myeloid leukemia (AML)
             /Acute lymphoblastic leukemia (ALL) / Acute undifferentiated leukemia (AUL) /Acute
             biphenotypic leukemia / Chronic myelogenous leukemia (CML) / Chronic lymphocytic
             leukemia (CLL) / myelodysplastic syndrome(s) (MDS)

          -  Subject is scheduled to receive an allogeneic peripheral blood stem cell (PBSC) or
             bone marrow transplant (BMT) for the treatment of hematologic disorders

        Exclusion Criteria:

          -  Subject has active CMV disease or infection or has received treatment for active CMV
             disease or infection within 90 days prior to transplant

          -  Subject has planned CMV prophylactic therapy with antiviral drugs or CMV-specific
             immunoglobulins

          -  Subject has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score
             &gt; 3

          -  Subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B
             surface antigen or hepatitis C ribonucleic acid (RNA)

          -  Subject has received any of the following substances or treatments:

               -  T-cell depletion of donor cell product.

               -  Tlemtuzumab within 60 days prior to transplant, including conditioning regimen.
                  Subjects for whom treatment with alemtuzumab is planned at any time from 60 days
                  prior to through one year post-transplant should not be enrolled in the trial.

               -  Administration of a CMV vaccine, including any prior exposure to ASP0113.

          -  Subject has received an allogeneic stem cell transplant within one year prior to
             transplant

          -  Subject has a current malignancy in addition to the malignancy being treated for the
             study or the subject has a history of any other malignancy

          -  Subject has an unstable medical or psychiatric condition, including a history of
             illicit drug(s) or alcohol abuse that the Investigator believes will interfere with
             protocol requirements.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>clintrialtrials_info@jp.astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytomegalovirus</keyword>
  <keyword>DNA vaccine</keyword>
  <keyword>transplantation</keyword>
  <keyword>HCT</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
